GlassScriptPhysician profile
Christopher S Mcfadden
NPI 1982247417
$9,597.17
in general payments reported to CMS, 2019-2025
23 companies · $2,655 in 2025
The $2,655 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $1,080 · 2023: $2,158 · 2024: $2,650 · 2025: $2,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,463.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.08 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,354.35 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $820.98 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $800.27 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $659.01 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $617.97 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $574.74 | 2022-2025 | Auvelity |
| Lundbeck LLC | $547.68 | 2021-2025 | Rexulti, Brintellix, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $484.38 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $423.38 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $339.77 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $280.96 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $215.80 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $208.98 | 2022-2025 | Invega, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $194.87 | 2022-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $155.56 | 2022-2025 | Azstarys |
| Indivior INC. | $138.23 | 2022-2024 | Perseris, Sublocade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $126.70 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $78.69 | 2024-2025 | Nuplazid |
| Collegium Pharmaceutical, INC. | $51.42 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $50.92 | 2022-2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $40.35 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $27.08 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.